naltrexone has been researched along with varenicline in 30 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (13.33) | 29.6817 |
2010's | 17 (56.67) | 24.3611 |
2020's | 9 (30.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Gilbert, M; Laustsen, G; Wimett, L | 1 |
Bartlett, SE; Holgate, J; Richards, JK; Simms, JA; Steensland, P | 1 |
Tyndale, R | 1 |
Kuehn, BM | 1 |
Brody, A; Courtney, KE; Ghahremani, DG; London, ED; Miotto, K; Ray, LA | 2 |
Bujarski, S; Ray, LA | 1 |
Fisher, DC; Fletcher, PJ; Guy, EG; Higgins, GA | 1 |
Lieb, M; Soyka, M | 1 |
Bujarski, S; Green, R; Hartwell, E; Ray, LA; Roche, DJ | 1 |
Klein, JW | 1 |
Dilley, JE; Filosa, NJ; Fischer, SM; Froehlich, JC; Nicholson, ER; Rademacher, LC; Smith, TN | 2 |
Lyon, J | 1 |
Bardo, MT; Bell, RL; Crooks, PA; Dwoskin, LP; Maggio, SE; Nixon, K; Prendergast, MA; Saunders, MA; Zheng, G | 1 |
Achenbach, C; Akanbi, MO; Bilaver, LA; Carroll, AJ; Hitsman, B; Jordan, N; McHugh, MC; Murphy, R; O'Dwyer, LC | 1 |
Lim, AC; Ray, LA; Roche, DJO | 1 |
Hauser, SR; Knight, CP; McBride, WJ; Pratt, LA; Rodd, ZA; Waeiss, RA | 1 |
Anton, RF; Falk, DE; Fertig, J; Hasin, DS; Johnson, B; Kranzler, HR; Litten, RZ; Mann, KF; Meulien, D; O'Malley, SS; Ryan, M; Slater, M; Witkiewitz, K | 1 |
Ayers, C; Chan, B; Freeman, M; Kansagara, D; Kondo, K; Montgomery, J; Paynter, R | 1 |
Bardo, MT; Chandler, CM; Maggio, SE; Nixon, K; Peng, H | 1 |
Kenny, PJ; O'Brien, CP; Pierce, RC; Swinford-Jackson, SE; Unterwald, EM; Vanderschuren, LJMJ | 1 |
Grodin, EN; Ho, D; Ray, LA; Towns, B | 1 |
Enders, C; Green, R; Grodin, EN; Hartwell, E; Ho, D; Leventhal, AM; Li, G; Lim, A; Meredith, L; Miotto, K; Nieto, SJ; Ray, LA; Shoptaw, S; Venegas, A | 1 |
Burnette, EM; Green, R; Grodin, EN; Lim, AC; Miotto, K; Ray, LA | 1 |
Kalin, NH | 1 |
Green, R; Montoya, AK; Ray, LA | 1 |
Green, R; Ray, LA; Roche, DJO | 1 |
Enders, CK; Nieto, SJ; O'Malley, SS; Ray, LA; Witkiewitz, K | 1 |
5 review(s) available for naltrexone and varenicline
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline | 2015 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
The efficacy of smoking cessation interventions in low- and middle-income countries: a systematic review and meta-analysis.
Topics: Adult; Behavior Therapy; Bupropion; Cigarette Smoking; Clonidine; Counseling; Developing Countries; Humans; Mobile Applications; Naltrexone; Nortriptyline; Randomized Controlled Trials as Topic; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Varenicline | 2019 |
Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis.
Topics: Amphetamine-Related Disorders; Anticonvulsants; Antidepressive Agents; Antipyretics; Drug Therapy; Humans; Methylphenidate; Naltrexone; Outcome Assessment, Health Care; Varenicline | 2019 |
9 trial(s) available for naltrexone and varenicline
Article | Year |
---|---|
Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.
Topics: Adult; Alcohol Drinking; Benzazepines; Craving; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult | 2014 |
Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.
Topics: Adult; Alcoholism; Benzazepines; Brain; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2015 |
Negative affect is associated with alcohol, but not cigarette use in heavy drinking smokers.
Topics: Adult; Affect; Alcohol-Related Disorders; Benzazepines; Comorbidity; Craving; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Psychiatric Status Rating Scales; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult | 2014 |
Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.
Topics: Adult; Alcohol Drinking; Double-Blind Method; Female; Humans; Male; Naltrexone; Smoking; Smoking Cessation; Varenicline | 2015 |
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Risk Assessment; Topiramate; Varenicline | 2019 |
A novel human laboratory model for screening medications for alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Humans; Laboratories; Naltrexone; Varenicline | 2020 |
Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Cholinergic Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Smoking Cessation; Smoking Cessation Agents; Varenicline | 2021 |
The Effects of Menstrual Cycle Hormones on Responses to Varenicline and Naltrexone Among Female Heavy Drinking Smokers.
Topics: Double-Blind Method; Female; Hormones; Humans; Male; Menstrual Cycle; Naltrexone; Smokers; Varenicline | 2022 |
Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Naltrexone; Treatment Outcome; Varenicline; World Health Organization | 2022 |
16 other study(ies) available for naltrexone and varenicline
Article | Year |
---|---|
Drug approvals.
Topics: Acetanilides; Alprostadil; Angina Pectoris; Benzazepines; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fatty Acids; Herpes Zoster Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Ibandronic Acid; Insulin; Lubiprostone; Naltrexone; Narcotic Antagonists; Nurse's Role; Papillomavirus Vaccines; Patient Education as Topic; Piperazines; Quinoxalines; Ranolazine; Triazoles; United States; United States Food and Drug Administration; Varenicline | 2007 |
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.
Topics: Animals; Appetite; Behavior, Addictive; Behavior, Animal; Benzazepines; Ethanol; Male; Naltrexone; Nicotinic Agonists; Quinoxalines; Rats; Receptors, Nicotinic; Sensitivity and Specificity; Sucrose; Varenicline; Water | 2007 |
Drug addiction: a critical problem calling for novel solutions.
Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Harm Reduction; Humans; Marijuana Smoking; Naltrexone; Narcotic Antagonists; Prevalence; Privacy; Quinoxalines; Receptors, Nicotinic; Recurrence; Risk-Taking; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Substance-Related Disorders; Varenicline | 2008 |
Findings on alcohol dependence point to promising avenues for targeted therapies.
Topics: Alcoholism; Animals; Benzazepines; Humans; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Nicotinic Agonists; Pharmacogenetics; Pyridines; Quinoxalines; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid, mu; Stress, Psychological; Triazoles; Varenicline | 2009 |
Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats.
Topics: Animals; Benzazepines; Bupropion; Cholinergic Agents; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Male; Naltrexone; Narcotic Antagonists; Nicotine; Quinoxalines; Rats; Rats, Long-Evans; Reinforcement, Psychology; Varenicline | 2014 |
Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.
Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Rats; Rodentia; Treatment Outcome; Varenicline | 2016 |
A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking.
Topics: Alcohol Drinking; Animals; Drug Therapy, Combination; Genetic Predisposition to Disease; Male; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Rats; Varenicline | 2017 |
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline | 2017 |
An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Disease Models, Animal; Ethanol; Female; Naltrexone; Nicotine; Nicotinic Antagonists; Picolines; Pyridinium Compounds; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2018 |
Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers.
Topics: Adult; Alcohol Drinking; Alcoholism; Cigarette Smoking; Craving; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Smokers; Smoking Cessation; Stress, Psychological; Varenicline; Young Adult | 2018 |
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Injections, Subcutaneous; Naltrexone; Nicotine; Random Allocation; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline | 2019 |
Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Male; Naltrexone; Nicotine; Rats; Rats, Sprague-Dawley; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline | 2020 |
The Persistent Challenge of Developing Addiction Pharmacotherapies.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bupropion; Central Nervous System Stimulants; Cocaine-Related Disorders; Drug Therapy; Humans; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Smoking Cessation Agents; Substance-Related Disorders; Varenicline | 2021 |
Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers.
Topics: Alcohol Drinking; Alcoholism; Cues; Double-Blind Method; Humans; Naltrexone; Smokers; Varenicline | 2021 |
Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities.
Topics: Alcoholism; Anorexia Nervosa; Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Patient Outcome Assessment; Schizophrenia; Smoking; Varenicline | 2021 |
The relationship between drinking and smoking in a clinical trial for smoking cessation and drinking reduction.
Topics: Alcohol Drinking; Naltrexone; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2022 |